Casdin Partners Master Fund, L.P. - May 23, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director, 10%+ Owner
Signature
Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member
Stock symbol
LAB
Transactions as of
May 23, 2024
Transactions value $
$260,000
Form type
4
Date filed
5/28/2024, 08:45 PM
Previous filing
May 22, 2024
Next filing
Jun 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Purchase $260K +100K +0.22% $2.60 46.1M May 23, 2024 See footnote F1
holding LAB Common Stock 13.9M May 23, 2024 See footnote F2
holding LAB Common Stock 104K May 23, 2024 Direct F3
holding LAB Common Stock 2.74M May 23, 2024 See footnote F4
holding LAB Common Stock 1.2M May 23, 2024 See footnote F5
holding LAB Common Stock 7.55M May 23, 2024 See footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F2 The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F3 The securities are owned directly by Eli Casdin.
F4 The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F5 The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F6 The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.

Remarks:

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.